Alnylam Pharmaceuticals, Inc. · NASDAQ:ALNY

Alnylam Pharmaceuticals — Clinical Trials on Alzheimer's Disease (CTAD) Conference 2024

21 slides from Alnylam Pharmaceuticals's conference presentation, Nov 1, 2024

  1. Slide 1: Design and Rationale of cAPPricorn-1, a Phase 2 Study of Mivelsiran in CAA

    Design and Rationale of cAPPricorn-1, a Phase 2 Study of Mivelsiran in Patients with Cerebral Amyloid Angiopathy Jin-Moo Lee1, Ellis S. van Etten2, Matthijs J. P. van Osch2, Catharina J. M. Klijn3, Alexandre Sostelly4, Sasikiran Goteti4, Farshid Sepehrband5, Andreja Avbersek5, Robert W. Deering4, Ne

  2. Slide 2: Disclosures

    Disclosures Presenter: Jin-Moo Lee, MD, PhD Conflict Disclosure NIH R01NS120481, R37NS110699, UFNS125512, Research Support RF1NS139970, R01NS120481, RF1AG079503 Unpaid Advisory Committee Member Alnylam Pharmaceuticals Mivelsiran: Mivelsiran is an investigational drug being studied for the treatment

  3. Slide 3: CAA and AD are Distinct but Related Diseases Linked by Aβ

    CAA and AD are Distinct but Related Diseases Linked by Aβ In CAA, Progressive Aβ Accumulation Leads to Vascular Disease, Debilitating Strokes, and Cognitive Decline • Cerebral amyloid angiopathy (CAA) is characterized by progressive deposition of Aβ in cerebral blood vessels1 • Manifestations includ

  4. Slide 4: Aβ Precursor Protein (APP) is the Source of Aβ

    Aβ Precursor Protein (APP) is the Source of Aβ Aβ is Derived from APP and is Deposited in Vessels APP Structure8,a • APP is a transmembrane protein that is cleaved to produce a variety of peptides, including Aβ1 • Vascular amyloid deposits are largely composed of Aβ40, and parenchymal plaques are mo

  5. Slide 5: RNA Interference Harnesses an Endogenous Process to Lower Expression of Disease-Associated Proteins

    RNA Interference Harnesses an Endogenous Process to Lower Expression of Disease-Associated Proteins Such as APP • RNA interference (RNAi) is a natural RNAi Mechanism of Action3,a process that regulates gene expression1 Synthetic gene-specific siRNA • Synthetic small interfering RNAs (siRNAs) are des

  6. Slide 6: Intrathecal Delivery of C16-Conjugated siRNA Enables CNS Targeting in Preclinical Models

    Intrathecal Delivery of C16-Conjugated siRNA Enables CNS Targeting in Preclinical Models, Supporting Clinical Development • In preclinical models, intrathecally administered C16-conjugated siRNA enabled distribution throughout the CNS and durable target engagement in the deep brain,1 supporting deve

  7. Slide 7: Mivelsiran is an Investigational RNAi Therapeutic Designed to Reduce APP Production in the CNS

    Mivelsiran is an Investigational RNAi Therapeutic Designed to Reduce APP Production in the CNS Mivelsiran is Being Evaluated in AD and in CAA Phase 1 Early-Onset AD Single and Multiple Ascending Dose Study (ongoing)1 AD (e.g., early-onset AD, autosomal dominant AD, Down syndrome AD) Phase 2 CAA cAPP

  8. Slide 8: Single Doses of Mivelsiran Reduced CSF sAPPβ and Aβ40 in a Phase 1 Study

    Single Doses of Mivelsiran Reduced CSF sAPPβ and Aβ40 in a Phase 1 Study of Patients With Early-Onset ADa,1 sAPPβ Aβ40 Mivelsiran has shown robust and durable reductions of amyloidogenic proteins in early-onset AD, supporting its further evaluation in CAA1,2 NCT05231785. Data shown as of August 2, 2

  9. Slide 9: Phase 1 Safety Profile in Patients with Early-Onset AD Supports Continued Development

    Phase 1 Safety Profile in Patients with Early-Onset AD Supports Continued Development of Mivelsiran1 Mivelsiran 25 mg Mivelsiran 35 mg Mivelsiran 50 mg Mivelsiran 75 mg Patients with events or placebo or placebo or placebo or placebo (N=6, PY=6.9) (N=8, PY=4.8) (N=8, PY=7.6) (N=14, PY=13.5) Time fro

  10. Slide 10: Mivelsiran Phase 1 and Phase 2 Development Overview

    Mivelsiran Phase 1 and Phase 2 Development Overview Phase 1 Early-Onset AD Early-Onset Alzheimer’s Disease Single and Multiple Ascending Dose Study (ongoing)1 AD (e.g., early-onset AD, autosomal dominant AD, Down syndrome AD) Phase 2 CAA cAPPricorn-1: Phase 2 study in sporadic and Dutch-type CAA2 AD

  11. Slide 11: cAPPricorn-1 is a Phase 2 Study in Sporadic or Hereditary CAA

    cAPPricorn-1 is a Phase 2 Study Evaluating Mivelsiran in Patients with Sporadic or Hereditary CAA Sporadic CAA Dutch-type CAA Rationale: Rationale: • High prevalence, later onset • Rapidly progressive, genetically defined • Significant unmet need to reduce risk of hemorrhagic • Earlier onset with fe

  12. Slide 12: cAPPricorn-1 Study Design

    cAPPricorn-1 Study Design Phase 2 Multiple-Dose Study Evaluating Efficacy, Safety, and Pharmacodynamics Sporadic CAAa R (Primary Efficacy Cohort) Mivelsiran IT Safety Mivelsiran IT follow-up Placebo IT Dutch-type CAAa R (Descriptive Cohort) Double-Blind Treatment Period Optional Open-Label Extension

  13. Slide 13: cAPPricorn-1 will Evaluate Complementary Hemorrhagic and Non-Hemorrhagic Outcome Measures

    cAPPricorn-1 will Evaluate Complementary Hemorrhagic and Non-Hemorrhagic Outcome Measures Efficacy will be Assessed up to 24 Months and Safety up to 48 Months Measure Description Annualized rate of new lobar cerebral microbleeds on MRI Primary Endpointa Novel global rank endpoint integrating clinica

  14. Slide 14: cAPPricorn-1 Overall Study Design

    cAPPricorn-1 Overall Study Design A Phase 2 Multiple-Dose Study Evaluating Efficacy, Safety, and Pharmacodynamics of Mivelsiran in Patients with CAA Study Population (N~200) Sporadic CAA Cohort Outcome Measuresa • Age ≥50 years Primary endpoint Sporadic • Probable CAA (Boston v2.0 Annualized rate of

  15. Slide 15: Summary

    For US HCPs Only Scan to View Congress Summary Material Presented For non-US HCPs, please contact [email protected] • CAA is characterized by cerebrovascular deposition of Aβ and is commonly comorbid with AD1,2 − CAA increases the risk of hemorrhagic strokes and independently contributes to progre

  16. Slide 16: Thank you to the patients, investigators and collaborators

    Thank you to the patients, their families, investigators, study staff, collaborators, and the Global Steering Committee for their support and participation in the ongoing cAPPricorn-1 study

  17. Slide 17: Back Up

    | || Back Up

  18. Slide 18: RNAi and ASO Therapeutics are Distinct Classes of Medicine

    RNAi and ASO Therapeutics are Distinct Classes of Medicine1 RNAi ASO Double- Activated siRNA–RISC– Degraded stranded siRNA guide strand Active complex fully RISC mRNA complex mRNA siRNA remains bound to dissociates after RNAi Nature of RISC and further cleavage;3,5 Interaction processes target recru

  19. Slide 19: Mivelsiran is an Investigational RNAi Therapeutic Designed to Reduce APP Production in the CNS

    Mivelsiran is an Investigational RNAi Therapeutic Designed to Reduce APP Production in the CNS • Intrathecally administered C16- Therapeutic Hypothesis of Mivelsiran in CAA conjugated siRNA enables cellular Nucleus APP gene uptake in the CNS1 • Reducing production of APP is expected to lower Aβ pept

  20. Slide 20: A Phase 1 Study Evaluating Safety and Efficacy of Single Ascending Doses of Mivelsiran

    A Phase 1 Study Evaluating Safety and Efficacy of Single Ascending Doses of Mivelsiran in Early-Onset AD1 An Ongoing, Double-Blind, Placebo-Controlled Study Primary Endpoint N=6 25 mg mivelsiran or placebo (randomized 2:1) Study Population (N=36) • Safety and tolerability (frequency of AEs) Adult pa

  21. Slide 21: Single Doses of Mivelsiran Reduced CSF sAPPα and Aβ42 in a Phase 1 Study

    Single Doses of Mivelsiran Reduced CSF sAPPα and Aβ42 in a Phase 1 Study of Patients With Early-Onset AD1 sAPPα Aβ42 Mivelsiran has shown robust and durable reductions of APP cleavage products in early-onset AD, supporting its further evaluation in CAA1,2 NCT05231785. Data shown as of August 2, 2024

Alnylam Pharmaceuticals — Clinical Trials on Alzheimer's Disease (CTAD) Conference 2024 on 6ix